Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Very early onset inflammatory bowel disease Indication Strategy Report 2026: IL-10, Trials and Deals
3 August 2026
2026 Very early onset inflammatory bowel disease indication strategy covering epidemiology, IL-10 biology, active trials, transactions, unmet need, competition…
Read →
Latest Hotspot
8 min read
Kindler epidermolysis bullosa Indication Strategy Report 2026: FERMT1, Trials and Deals
3 August 2026
2026 Kindler epidermolysis bullosa indication strategy covering epidemiology, FERMT1 biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Chronic granulomatous disease-associated colitis Indication Strategy Report 2026: NADPH oxidase, Trials and Deals
3 August 2026
2026 Chronic granulomatous disease-associated colitis indication strategy covering epidemiology, NADPH oxidase biology, active trials, transactions, unmet need,…
Read →
Latest Hotspot
8 min read
Epidermolysis bullosa simplex Indication Strategy Report 2026: KRT14, Trials and Deals
3 August 2026
2026 Epidermolysis bullosa simplex indication strategy covering epidemiology, KRT14 biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
IPEX-associated enteropathy Indication Strategy Report 2026: FOXP3, Trials and Deals
3 August 2026
2026 IPEX-associated enteropathy indication strategy covering epidemiology, FOXP3 biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Trichohepatoenteric syndrome Indication Strategy Report 2026: TTC37, Trials and Deals
3 August 2026
2026 Trichohepatoenteric syndrome indication strategy covering epidemiology, TTC37 biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Congenital tufting enteropathy Indication Strategy Report 2026: EPCAM, Trials and Deals
3 August 2026
2026 Congenital tufting enteropathy indication strategy covering epidemiology, EPCAM biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Cronkhite-Canada syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
3 August 2026
2026 Cronkhite-Canada syndrome indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Familial adenomatous polyposis Indication Strategy Report 2026: APC, Trials and Deals
3 August 2026
2026 Familial adenomatous polyposis indication strategy covering epidemiology, APC biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
MUTYH-associated polyposis Indication Strategy Report 2026: MUTYH, Trials and Deals
3 August 2026
2026 MUTYH-associated polyposis indication strategy covering epidemiology, MUTYH biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Juvenile polyposis syndrome Indication Strategy Report 2026: SMAD4, Trials and Deals
3 August 2026
2026 Juvenile polyposis syndrome indication strategy covering epidemiology, SMAD4 biology, active trials, transactions, unmet need, competition and market…
Read →
Latest Hotspot
8 min read
Cowden syndrome Indication Strategy Report 2026: PTEN, Trials and Deals
3 August 2026
2026 Cowden syndrome indication strategy covering epidemiology, PTEN biology, active trials, transactions, unmet need, competition and market attractiveness.
Read →
<
1
<<
273
274
275
276
277
>>
1486
>